

# VALUE ASSESSMENT SHOULD INCLUDE ALL ASPECTS OF VALUE THAT MATTER TO PATIENTS

We need to move toward a more value-driven health care system that centers around patients' needs. Sound evidence can help guide us toward that, and we're committed to developing tools to help patients, physicians and others make informed decisions.

## VALUE ASSESSMENTS, OR HEALTH TECHNOLOGY ASSESSMENTS, ARE ONE TOOL THAT CAN SUPPORT BETTER VALUE IN HEALTH CARE.

But current value assessments often fall short of the transparent, patient-centered approach we need. Value assessments should include all the outcomes that matter to patients and families, including those in disadvantaged and minority communities.


## CONVENTIONAL APPROACHES TO VALUE ASSESSMENT RELY ON FLAWED STANDARDS.

These include cost-effectiveness analysis (CEA) and quality-adjusted life years (QALYs) that ignore important elements of value that matter to patients and society.

## WHILE TRADITIONAL QALY-BASED COST-EFFECTIVENESS ANALYSES CAPTURE:


- Mortality
- Ability to care for oneself (e.g., dressing, hygiene)
- Ability to walk unassisted
- Pain or discomfort
- Ability to perform housework, study, leisure activities and other usual activities
- Anxiety or depression

## THEY MAY NOT TAKE INTO CONSIDERATION OTHER ELEMENTS THAT MATTER TO PATIENTS WITH:




### AMYOTROPHIC LATERAL SCLEROSIS (ALS) / LOU GEHRIG'S DISEASE<sup>1,2</sup>

- Ability to swallow without pain or risk of choking
- Ability to speak without a speech device
- Ability to use hands and arms



### NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD)<sup>5</sup>

- Frequency of infusions
- Cost and travel time for treatment
- Social isolation



### CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)<sup>3,4</sup>

- Reduced wheeziness or coughing up mucus
- Fatigue and sleep quality
- Frequency of treatment



### ALZHEIMER'S DISEASE<sup>6,7</sup>

- Reduced episodes of hallucinations and agitation
- Family and caregiver costs and well-being
- Ability to communicate and convey thoughts

Outcomes that matter to patients should matter to everyone.

LEARN MORE AT [PHARMA.ORG/VALUE-ASSESSMENT](https://www.pfizer.com/research/progress/hope)

## WORKS CITED:

1. Simmons, Z. (2014). Patient-perceived outcomes and quality of life in ALS. *Neurotherapeutics*, 12(2), 394-402. <https://doi.org/10.1007/s13311-014-0322-x>
2. Peters, N., Dal Bello-Haas, V., Packham, T., Chum, M., O'Connell, C., Johnston, W. S., MacDermid, J., Turnbull, J., Van Damme, J., & Kuspinar, A. (2021). Do generic preference-based measures accurately capture areas of health-related quality of life important to individuals with amyotrophic lateral sclerosis: A content validation study. *Patient Related Outcome Measures*, 12, 191-203. <https://doi.org/10.2147/prom.s313512>
3. Slejko, J.F., Hong, Y. D., Sullivan, J. L., Reed, R. M., dosReis, S. (2021). Prioritization and Refinement of Patient-Informed Value Elements as Attributes for Chronic Obstructive Pulmonary Disease Treatment Preferences. *The Patient - Patient-Centered Outcomes Research*, 14(5), 569-579. DOI: 10.1007/s40271-021-00495-2.
4. Slejko, J. F., Gray, C., Hong, Y., Rueda, J., Zhang, C., & dosReis, S. (2019). Aligning COPD Outcomes with Patient-Informed Value Element Domains for Use in Economic Evaluations. ISPOR Poster. Available at: [https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/pave/pdf/ispor-2019-poster\\_pave-value-element-alignment.pdf](https://www.pharmacy.umaryland.edu/media/SOP/wwwpharmacyumarylandedu/centers/pave/pdf/ispor-2019-poster_pave-value-element-alignment.pdf)
5. Forthcoming research from University of Colorado's pValue will identify priority value elements for patients with NMOSD. More information available at: <https://pharmacy.cuanschutz.edu/research/research-centers/pvalue>
6. Mank A., van Maurik IS., Bakker ED., van de Glind EMM., Jönsson L., Kramberger MG., Novak P., Diaz A., Gove D., Scheltens P., van der Flier WM., Visser LNC. (2021). Identifying Relevant Outcomes in the Progression of Alzheimer's Disease: What Do Patients and Care Partners Want to Know about Prognosis? *Alzheimers Dement*, 20;7(1). DOI: 10.1002/trc2.12189.
7. Barrios PG., González RP., Hanna SM., Lunde AM., Fields JA., Locke DE., Smith GE. (2016). Priority of Treatment Outcomes for Caregivers and Patients with Mild Cognitive Impairment: Preliminary Analyses. *Neurol Ther*, 5(2):183-192. DOI: 10.1007/s40120-016-0049-1.